Medindia
Advertisement

FDA Accredits New Combination Painkillers Designed to Discourage Abuse

by Vishnuprasad on July 26, 2014 at 6:31 PM
Font : A-A+

FDA Accredits New Combination Painkillers Designed to Discourage Abuse

The U.S. Food and Drug Administration (FDA) has accredited a latest combination pain pill from the maker of OxyContin that is designed to discourage abuse by painkiller addicts.

Purdue Pharma's new drug Targiniq ER is an extended release tablet that blends oxycodone — the active ingredient in OxyContin — with the drug naloxone.

Advertisement

FDA regulators accredited the drug for daily, round-the-clock pain that does not react to other medications.

If abusers pulverize the tablets for snorting or injecting naloxone blocks the rhapsodic effects of oxycodone, making the drug more hard to abuse.
Advertisement

Naloxone is now utilized to reverse the overdose effects of opioids, highly addictive painkilling drugs including morphine, methadone, codeine and others.

The FDA notes that Targiniq can still be abused by simply swallowing the tablets, the most common way of painkiller abuse.

The Administration has been under pressure to combat the national epidemic of prescription opioid abuse.

Deaths related to addictive medications like OxyContin and Vicodin have increased fourfold since 1990 to an estimated 16,500 in 2010, the most recent year for which the Centers for Disease Control and Prevention reports figures.

Doctors prescribe opioids for a wide range of diseases, from post-surgical pain to arthritis and migraines.

Stamford, Connecticut-based Purdue has often been cited by health experts as a key contributor to the over prescribing of opioids.

In 2007, Purdue Pharma and three of its executives paid $634 million and pleaded guilty to charges of providing wrong ideas to the public about the safety and addictiveness of OxyContin.

Since then the pharmaceutical company introduced a harder-to-abuse version of OxyContin that is designed to resist crushing, chewing and dissolving.

Dr. Sharon Hertz of the FDA commented that the Administration is committed to combating the misuse of all opioids, and the development of opioids that are harder to abuse is needed in order to help address the public health crisis of prescription drug abuse.

The FDA is requiring Purdue to carry out long-term follow-up researches tracking rates of abuse, addiction, overdose and death with Targiniq.

Those requirements are benchmark for all extended release opioid drugs approved in the State.



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
World Alzheimer's Day 2021 - 'Know Dementia, Know Alzheimer's
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
Stroop Effect
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Endorphins Painkiller Addiction Top 15 Natural Painkillers Prescription Drug Abuse 

Recommended Reading
Drug Abuse
The use of Drugs for reasons other than its prescribed recommendation, is known as Drug abuse or ......
Drug Abuse in Pregnancy
Drug abuse during pregnancy has an adverse effect on the mother as well as the fetus. It is ......
Endorphins
Endorphins are natural painkillers produced in response to stimuli, like laughter, pain, stress, sex...
Painkiller Addiction
Painkiller addiction is the use of prescription painkillers in a way not meant by the prescribing do...
Prescription Drug Abuse
Prescription drug abuse is consuming prescription medications in a way different from that as prescr...
Top 15 Natural Painkillers
Natural painkillers, such as herbs and spices can relieve pain too. They can be as potent and effect...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use